Tamoxifen therapy conveys increased risk of developing a macular hole

International Ophthalmology

Volumn 26, Issue 3, 2005, Pages 101-105

  Cronin, Brendan G ^a   Lekich, Christopher K ^a   Bourke, Robert D ^a,b  

^a The Eye Centre ^*  (Australia)

^b Eye Centre   (Australia)

Author keywords

ILM; Internal limiting membrane; Macular hole; Oestrogen; Retinopathy; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ANAMNESIS; ARTICLE; AUSTRALIA; CILIARY DISK; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PATIENT COUNSELING; POPULATION RESEARCH; PREVALENCE; PUBLISHING; RETINA MACULA HOLE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGEON; SYMPTOMATOLOGY; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETINAL PERFORATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; VITRECTOMY;

EID: 33751225938     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-005-5424-3     Document Type: Article

References (19)

1. Aaberg TM, Blair CJ and Gass JD (1970). Macular holes. Am J Ophthalmol 69: 555-562
2. Smiddy WE and Flynn J (2004). Pathogenesis of macular holes and therapeutic implications. Am J Ophthalmol 137: 525-537
3. Yooh HS, Brooks HL Jr., Capone A Jr. (1996). Ultrastructural features of tissue removed during idiopathic macular hole surgery. Am J Ophthalmol 122: 67-75
4. Gass JD (1995). Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 119: 752-759
5. la Cour M, Friis J (2002). Macular holes: Classification, epidemiology, natural history and treatment. Acta Ophthalmol Scand 80: 579-587
6. Drug Information Sheet for Nolvadex(TM) Tamoxifen Citrate. 2004. ZENECA Pharmaceuticals
7. Australian Bureau of Statistics. Census Population Data for 30 June 2003
8. Evans JR, Schwartz SD and McHugh JD (1998). Systemic risk factors for idiopathic macular holes: A case-control study. Eye 12: 256-259
9. McDonnell PJ, Fine SL and Hillis AI (1982). Clinical features of idiopathic macular cysts and holes. Am J Ophthalmol 93: 777-786
10. Risk factors for idiopathic macular holes. The Eye Disease Case-Control Study Group. Am J Ophthalmol 1994; 118: 754-761
11. Pavlidis NA, Petris C and Briassoulis E (1992). Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular-toxicity. A prospective study of 63 patients. Cancer 69: 2961-2964
12. Alwitry A and Gardner I (2002). Tamoxifen maculopathy. Arch Ophthalmol 120: 1402
13. Imperia PS, Lazarus HM and Lass JH (1989). Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 34: 209-230
14. Noureddin BN, Seoud M and Bashshur Z (1999). Ocular toxicity in low-dose tamoxifen: A prospective study. Eye 13: 729-733
15. Lazzaroni F, Scorolli L and Pizzoleo CF (1998). Tamoxifen retinopathy: does it really exist?. Graefes Arch Clin Exp Ophthalmol 236: 669-673
16. Kaiser-Kupfer MI and Lippman ME (1978). Tamoxifen retinopathy. Cancer Treat Rep 62: 315-320
17. Yanyali AC, Freund KB and Sorenson JA (2001). Tamoxifen retinopathy in a male patient. Am J Ophthalmol 131: 386-387
18. Sadowski B, Kriegbaum C and Apfelstedt-Sylla E (2001). Tamoxifen side effects, age-related macular degeneration (AMD) or cancer associated retinopathy (CAR)?. Eur J Ophthalmol 11: 309-312
19. Kaiser-Kupfer MI, Kupfer C and Rodrigues MM (1981). Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 88: 89-93